4135 results about "Cancer cell" patented technology

The invention relates to the technical field of data mining and analysis, in particular to a knowledge mining method and system for the tumor field. The method comprises the following steps: acquiring a tumor multi-source heterogeneous data set, and performing data standardization processing to obtain a standardized tumor multi-source heterogeneous data set; performing multi-level feature extraction on the standardized tumor multi-source heterogeneous data set to obtain a tumor fusion feature set; performing hierarchical knowledge graph construction based on the tumor fusion feature set to obtain a tumor hierarchical knowledge graph; and constructing a graph neural network model by using the tumor hierarchical knowledge graph, and carrying out cancer cell dynamic prediction to obtain tumor dynamic knowledge reasoning result data. According to the method, cancer cell prediction is carried out by extracting the multi-level features, constructing the hierarchical knowledge graph and applying the graph neural network, and personalized medical research optimization is provided, so that the accuracy of cancer cell prediction and the personalization of the medical research direction are remarkably improved.

This disclosure relates to dimeric immunoconjugates for use in treating cancer generally and to dimeric immunoconjugates that bind human sperm protein 17 (Sp17) specifically. A dimeric immunoconjugate of this disclosure generally comprises a first monomeric antibody that carries a first payload and a second monomeric antibody that carries a second payload, wherein the first payload and the second payload are different. Such dimeric immunoconjugates advantageously allow the simultaneous delivery of two chemotherapeutics to a cancer cell, which allows for synergistic antineoplastic activity.

The invention discloses a tryptamine compound as well as a preparation method and application thereof. The tryptamine compound can be used for preparing medicines for preventing and / or treating cancers. The cancer is at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on a plurality of compounds, the three tryptamine compounds provided by the invention are found to have excellent inhibitory activity on a plurality of different types of human cancer cells for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

The invention discloses a combination of different nucleic acid aptamers with known 291 targets, sequences of the nucleic acid aptamers of the combination are subjected to sequencing analysis through a single-cell high-throughput sequencing technology, and a cell map aiming at peripheral blood-derived mononuclear cells of a biliary tract cancer patient can be constructed. The nucleic acid aptamers covered by the combination have high specific affinity to molecular targets of the nucleic acid aptamers, and after the two ends of the nucleic acid aptamer sequences extend to adapt to joints of a commercial sequencing platform, high-throughput sequencing is carried out on the nucleic acid aptamer sequences which are combined with the surfaces of mononuclear cells and are provided with the sequencing joints; high-throughput analysis of the biomarkers on the surface of the peripheral blood-derived mononuclear cell of a biliary tract cancer patient can be realized, so that the cell map of the peripheral blood-derived mononuclear cell of the biliary tract cancer is constructed.

Disclosed are systems and methods for identifying prostate cancer patients at high-risk of progression among clinically intermediate risk group. Images of patient cells are obtained and tiled into subsets of smaller images. Using a trained machine learning model, a morphology quantification process is performed on the subsets of smaller images. Portions of the images are input into the trained machine learning models. The trained machine learning model determines the occurrence of likely cancer cells and classifies the cancer cells with a grading. The system then uses this out of the machine learning model to identify whether the cells in the subsets of smaller images indicate whether a prostate cancer patient is at a risk of progression among a clinically intermediate risk group.

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention discloses sesquiterpenoids as well as a preparation method and application thereof. The structure of the sesquiterpenoids is shown in the specification. The sesquiterpenoids of # imgabs0 can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, kidney cancer and skin cancer. According to the invention, various natural product extracts are subjected to activity screening, the sesquiterpenoids derived from the rattan chrysanthemum have excellent inhibitory activity on various different types of human cancer cells, and an optional scheme is provided for broad-spectrum anti-cancer drugs. The sesquiterpenoids applied in the invention are derived from rattan chrysanthemum, the source is wide, and the production cost is low.

The invention discloses a deep learning-based lung cancer early screening system, and particularly relates to the technical field of medical assistance, which comprises an intelligent data ecological module, an intelligent analysis and diagnosis module, an intelligent decision support module and a user interaction management module. According to the invention, cross-mechanism data sharing and cooperative training are realized by using data semantic understanding and federated sharing technologies, transparency and traceability of data are ensured through a block chain technology, and in an intelligent analysis and diagnosis module, a deep learning model comprehensively analyzes a multi-modal image and identifies molecular features of cancer cells, so that the accuracy of cancer diagnosis is improved. Potential early-stage lung cancer signs are found through an unsupervised learning algorithm, individual risks are dynamically evaluated, focus development is tracked, and an intelligent decision support module combines personalized treatment suggestions, optimizes clinical pathways and multidisciplinary collaboration, provides accurate decision suggestions and assists doctors in making scientific and effective treatment schemes.

The invention discloses a CA9-targeted chimeric antigen receptor and application thereof, and belongs to the technical field of biological medicines. The CA9 targeting chimeric antigen receptor provided by the invention comprises a CD8 alpha leading signal peptide, an anti-CA9 single-chain variable fragment, a CD8 alpha hinge, a CD8 transmembrane structural domain and a CD3 zeta intracellular costimulatory signal transduction structural domain. According to the invention, an anti-CA9 single-chain variable fragment is used as an antigen binding structural domain to construct a chimeric antigen receptor (CAR) molecule, the macrophage expressing the anti-CA9CAR can realize specific targeting and phagocytosis killing of CA9 positive kidney cancer cells, and the constructed lipid nanoparticle delivery system can effectively transfer a gene expression vector, so that the gene expression vector can realize effective target site delivery, and the CA9 positive kidney cancer cells can be effectively targeted and killed. The constructed hydrogel-liposome combined drug delivery system has the performance of relieving toxic and side effects, controllable release and hemostasis.

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of homologous recombination deficiency (HRD) or an HRD signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an HRD signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

The present invention relates to sonosensitive liposomes and a method for preparing the same. The sonosensitive liposomes according to the present invention improve the delivery efficiency of encapsulated drugs, and are expected to exhibit various functions in the fields of cancer treatment and drug delivery carriers by improving drug delivery effects through targeted cancer cells when used in combination with ultrasonic treatment.

The invention discloses a fuel cell hybrid electric heavy truck power source optimization design method and system, and the method comprises the steps: building a target function of the total cost per unit travelled distance in a life cycle based on the basic parameters of a fuel cell, a power cell and a super capacitor, and the degradation parameters and hydrogen consumption of the fuel cell and the power cell; an energy management strategy of the fuel cell hybrid electric heavy truck is established based on the average required power of the truck and the SOC of the power cell and the super capacitor; and a cancer cell competition and transfer algorithm is adopted, under an energy management strategy, a minimum objective function meeting the driving working condition is searched, and energy size optimization is completed. According to the method, the power source of the fuel cell hybrid electric heavy truck is subjected to global optimization design by adopting the cancer cell competition and transfer algorithm, the service life of the power source is prolonged while the power performance of the truck is guaranteed, the manufacturing cost, degradation cost and hydrogen consumption of a hybrid power system are remarkably reduced, and the energy efficiency of the system is improved.

The invention discloses a PROTACs compound for targeted degradation of PRMT5 and application of the PROTACs compound. The PROTACs compound comprises a compound as shown in the following formula, and related analogues or pharmaceutically acceptable salts, metabolites or prodrugs of the compound: in the # imgabs0 # formula, X represents a ligand bound to PRMT5 protein, Z represents a ligand of E3 ubiquitin ligase, and Y represents a linking group for linking X and Z; according to the invention, CRBN is used as E3 ligase, and a series of PRMT5-targeted PROTAC degradation compounds are designed and synthesized. The compound can effectively induce PRMT5 degradation, significantly inhibit proliferation, growth, migration, infiltration, clone formation and metastasis of tumor cells, promote apoptosis of cancer cells, promote autophagy of the tumor cells, prevent or overcome drug resistance of BTK inhibitors and / or prolong the lifetime of tumor patients, and has wide application prospects.

The invention belongs to the field of bioinformatics, and relates to an anti-cancer drug response prediction method based on an attention mechanism. The method comprises the following steps: firstly, capturing uniform-dimension drug and cancer cell line characteristics through a multi-layer perceptron; secondly, fusing drug characteristics by adopting a Transform encoder, and constructing a cell encoder for cancer cell line characteristic polymerization; then, designing a cross-modal cross fusion module to promote information interaction between the two; and finally, predicting a semi-suppressed concentration value subjected to logarithmic transformation between the two through a multi-layer perceptron. Experimental results show that compared with an existing optimal method, the method has the advantage that the RMSE is reduced by 2.9%. According to the method, accurate prediction of the anti-cancer drug response is achieved by integrating drug and cancer cell line data, screening of potential anti-cancer drugs can be accelerated, personalized treatment schemes can be optimized, the cure rate of cancer patients is further increased, and the method has great significance in cancer treatment.

The invention discloses an application of a therapeutic target spot in preparation of a drug for treating targeted therapy resistance of kidney cancer. The therapeutic target spot is SLC27A3. The SLC27A3 comprises an SLC27A3 gene and a coding sequence thereof, an expression product of the SLC27A3 gene and a coding sequence thereof, and the SLC27A3 gene and an active fragment or derivative of the expression product thereof; the nucleotide of the SLC27A3 is as shown in SEQ ID NO. 1. According to the invention, a therapeutic target SLC27A3 is knocked out or silenced, and a compound Parishin for resisting the SLC27A3 protein is provided, so that the resistance of renal clear cell carcinoma cells to the pezopanib is remarkably improved, and the sensitivity of renal carcinoma cells to the pezopanib is enhanced.

A device for modelling physiological and pathophysiological states of the brain is provided. The device comprises a hydrogel with micropattern channels having a length, width and depth. The micropattern channels comprise cells selected from the group consisting of neurons, astrocytes, microglia, oligodendrocytes, neuronal organoids, cancer cells, cancer spheroids, brain tumoral cells and combinations thereof.

There is described herein a pan-cancer transcriptional signature. In one aspect, there is described a method of diagnosing cancerous cells in a patient, the method comprising: a) providing a sample containing genetic material from patient cells suspected of being cancerous; b) determining or measuring expression levels in the patient cells of at least 3 of the 1919 genes listed in Table B; c) computing a score using a classifier that takes said expression level values as input, the classifier having been previously trained on known cancerous and non-cancerous samples; wherein the score provides a likelihood of a cancerous cell.

The invention relates to the technical field of spectral imaging detection, in particular to a spontaneous-stimulated Raman co-localization single-cell substructure atlas analysis system and a spontaneous-stimulated Raman co-localization single-cell substructure atlas analysis method. The system comprises a femtosecond pulse excitation module used for outputting two beams of broadband femtosecond pulse laser with different frequencies and continuously adjustable optical power; the Stokes light modulation module is used for modulating the Stokes light and carrying out space beam combination on the Stokes light and the pump light; the pump light modulation module is used for modulating pump light; the spontaneous Raman laser continuous adjusting module is used for outputting spontaneous Raman laser; the stimulated Raman exciting light co-positioning module is used for combining the combined laser and the spontaneous Raman laser again, focusing the combined laser and the spontaneous Raman laser on a sample, exciting a stimulated Raman scattering signal, converting the stimulated Raman scattering signal into a digital signal and carrying out data acquisition; and the spectrum detection module is used for collecting the spontaneous Raman scattering light which is reflected and returned along the original light path, and collecting a spectrum signal to form a Raman spectrum. The method has the advantage of improving the accuracy of single-cell heterogeneity structure and cancer cell type discrimination.

The invention belongs to the technical field of medicine synthesis, and particularly relates to an inhibitor compound, application and a medicine for treating cancer. The invention provides an inhibitor compound or a pharmaceutically acceptable salt, which can be used for preparing an EGFR kinase inhibitor and preparing a medicine for treating or preventing cancers. The present invention also provides medicaments for the treatment of cancer comprising the inhibitor compound or a pharmaceutically acceptable salt. The compound or the medicine provided by the invention is efficient and low in toxicity, not only has higher anti-tumor activity and can effectively inhibit the growth of cancer cells, but also keeps higher brain permeability, and has wide application prospects.

Described herein are synthetic promoters and / or enhancers that are specific for cancer cells and methods of engineering synthetic cancer-specific promoters.

The invention provides a mammary gland pathological cell image detection method and system based on an improved YOLOv7 model, and the method comprises the steps: S1, collecting mammary gland pathological section images, and generating a data set; s2, carrying out frame labeling on cells obtained in the data set; s3, segmenting the marked data set into a training set and a verification set; step S4, establishing a YOLOv7 network, and respectively adding an ASFF module and a CBAM module in three branches of the YOLOv7 network to obtain an improved YOLOv7 network; and S5, inputting the training set into the improved YOLOv7 network for training, and verifying to obtain the high-precision breast pathological section cell detection model. The improved model can effectively avoid a large semantic gap between non-adjacent levels of mammary gland cell characteristics, greatly enhance the detection capability of multi-scale cell targets such as tiny early cancer cells and large normal mammary gland tissue cells, and improve the recognition precision of early mammary gland lesion cells.

The present invention discloses the application of liver cancer cell ferroptosis inducer miR‑11085‑5p in the preparation of liver cancer treatment drugs, and innovative applications in the field of liver cancer treatment, specifically to the application of liver cancer cell ferroptosis inducer miR‑11085‑5p in the preparation of liver cancer treatment drugs. The present invention adopts lentiviral transfection technology to synthesize miR‑11085‑5p in vitro, and introduce it into liver cancer cells, and effectively induce liver cancer cells to undergo ferroptosis by precisely regulating the key signaling pathway of intracellular AMPKα / Nrf2, significantly inhibiting its proliferation activity. Therefore, for the disadvantages of low efficiency, large side effects and easy recurrence and metastasis of existing treatment methods for liver cancer, the miR‑11085‑5p provided by the present invention may become a biological preparation for the treatment of liver cancer, with potential drug development value, and provide a new solution for the treatment of liver cancer.

The present invention discloses a combination of different nucleic acid aptamers with 291 known targets. By performing sequencing analysis on the nucleic acid aptamer sequences of this combination through single-cell high-throughput sequencing technology, a cell atlas targeting mononuclear cells derived from the peripheral blood of patients with cholangiocarcinoma can be constructed. The nucleic acid aptamers covered by this combination have high specific affinity for their molecular targets. After extending adapters commercialized for sequencing platforms at both ends of the nucleic acid aptamer sequences respectively, by performing high-throughput sequencing on the nucleic acid aptamer sequences with sequencing adapters bound to the surface of mononuclear cells, high-throughput analysis of biomarkers on the surface of mononuclear cells derived from the peripheral blood of patients with cholangiocarcinoma can be achieved, thereby constructing a cell atlas of mononuclear cells derived from the peripheral blood of cholangiocarcinoma.

The invention provides a lentivirus for treating cancer as well as a preparation method, application and a corresponding pharmaceutical composition of the lentivirus. According to the invention, an hTERT promoter and a CDC6shRNA gene sequence are inserted behind an enzyme cutting site of a vector, an obtained plasmid is transferred into an expression strain, the expression strain is cultured and screened to obtain a cloned strain, and the cloned strain is shaken and packaged to obtain the hTERT-CDC6shRNA lentivirus; when the lentivirus disclosed by the invention is used for infecting cancer cells, the experimental result shows that the proliferation of the cancer cells can be effectively inhibited.

The invention discloses a micromolecule NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a micromolecular NSD3 degradation agent, which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The small molecule NSD3 degradation agent provides a new scheme for treatment of lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

This document provides methods and materials involved in assessing samples (e.g., cancer cells) for the presence of a loss of heterozygosity (LOH) signature. For example, methods and materials for determining whether or not a cell (e.g., a cancer cell) contains an LOH signature are provided. Materials and methods for identifying cells (e.g., cancer cells) having a deficiency in homology directed repair (HDR) as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen also are provided.

The invention discloses an establishment method and application of a mouse gastric cancer orthotopic transplantation model, and the establishment method comprises the following steps: injecting a mouse gastric adenocarcinoma cell line MKC1 (Mus musculus) into a mouse gastric tissue, and feeding to obtain the mouse gastric cancer orthotopic transplantation model. Compared with the prior art, the mouse gastric cancer in-situ model established in the invention has the advantages of strong repeatability in the construction process and good passage stability, especially can form tumor subcutaneously in a C57BL / 6 mouse with a sound immune system, has a therapeutic response to immunotherapeutic drugs such as anti-PD-1 monoclonal antibody, and is suitable for research on gastric cancer immune microenvironment and drug resistance mechanism of immunotherapeutic drugs.

Described herein are programmable DNA proteolytic target chimera complexes that can be used both for the direct treatment of cancer by inhibiting biochemical pathways that are overexpressed in cancer cells, and for the indirect treatment of cancer by recruiting the E3 ligase complex to engage with a protein of interest or a mutant thereof and initiating proteolysis. Also described herein are methods of using the complexes in the treatment of cancer, as well as compositions comprising the complexes.

The invention relates to a core-shell structure drug-loaded magnetic-thermal hydrogel microsphere for treating drug-resistant ovarian cancer and a preparation method thereof, belonging to the field of biological and medical micro-nano materials and technologies, and the core-shell structure drug-loaded magnetic-thermal hydrogel microsphere is formed by combining an inner core and a shell layer through covalent crosslinking and electrostatic interaction. An anti-tumor drug cis-platinum and magnetic nanoparticles are loaded on an inner core, and an AZ191 inhibitor is loaded on a chitosan shell, so that preferential release of AZ191 is realized to inhibit a drug-resistant signal channel and reduce the drug resistance of cancer cells, and the cis-platinum is slowly released after the action is completed to kill tumor cells. And the magnetic nanoparticles in the inner core can be heated under an external magnetic field, so that multifunctional synergistic treatment of magnetic hyperthermia, drug resistance inhibition and chemotherapy is realized. Chitosan and sodium alginate are biodegradable materials, so that the utilization rate of the embedded medicine can be increased, and meanwhile, the medicine can be metabolized out of a body. The preparation method does not relate to toxic cross-linking agents and organic solvents, and the prepared hydrogel core-shell microspheres have no biotoxicity. Complicated operation steps are not needed, the technological process is simple, the preparation period is short, and the application range is wide.

The invention relates to application of an ACBD3 inhibitor in preparation of a medicine for treating lung cancer and gRNA for inhibiting ACBD3 gene expression, and belongs to the field of bioengineering.199 binding proteins of ACBD3 are obtained through co-immunoprecipitation and mass spectrum identification, new biological functions of ACBD3 are excavated through GO analysis and KEGG pathway analysis of the binding proteins of ACBD3, and the application of the ACBD3 inhibitor in preparation of the medicine for treating lung cancer is developed. The ACBD3 is used for regulating and controlling a KEGG pathway enrichment map of a differential gene, and the ACBD3 is found to participate in the occurrence and development of cancers; the ACBD3 is successfully knocked out by designing gRNA, and tests prove that the multiple effects of slowing down A549 lung cancer cell proliferation, inhibiting lung cancer cell migration, inhibiting A549 lung cancer cell invasion, retarding A549 cell cycle G1 phase and reducing tumorigenicity can be achieved by knocking out the ACBD3.